Anti-HER2 Immunoconjugates for Targeted Cytotoxic Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional safe and effective agents that target HER2 for the treatment of HER2-associated conditions such as breast cancer, particularly in monotherapy and combination therapy.
Innovation Solution
Development of anti-HER2 antibodies and immunoconjugates that bind specifically to HER2, including specific amino acid sequences and structures, and can be used in combination with cytotoxic agents like auristatin, maytansinoid, calicheamicin, pyrrolobenzodiazepine, nemorubicin derivatives, or 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole, for targeted cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If trastuzumab is used as a mediator of antibody-dependent cellular cytotoxicity (ADCC), then HER2-positive cancer cell proliferation is inhibited, but additional safe and effective agents are needed to improve treatment outcomes
Solution Approach 1:
The patent combines trastuzumab with cytotoxic agents (auristatin, maytansinoid, calicheamicin, pyrrolobenzodiazepine, nemorubicin derivatives, or 1-(chloromethyl)-2,3-dihydro-1H-benzo[e]indole) to create immunoconjugates that merge the ADCC mechanism with direct cytotoxic effects, thereby improving treatment effectiveness while providing new therapy options for HER2-positive breast cancer
Solution Approach 2:
The immunoconjugates represent composite therapeutic agents that integrate the antibody trastuzumab with various cytotoxic drug moieties, creating hybrid molecules that exhibit both targeted binding to HER2 and potent cytotoxic activity, thus enhancing reliability and versatility of treatment
2Productivity
If existing anti-HER2 therapies are used, then some tumor reduction is achieved, but response rates are insufficient and more effective agents are required
Solution Approach 1:
The patent modifies the therapeutic parameters by conjugating trastuzumab with different cytotoxic agents having varying mechanisms of action and potencies, thereby changing the efficacy parameters to achieve higher response rates and improved tumor reduction while maintaining targeted delivery to HER2-positive cells
3Ease of operation
If monotherapy with anti-HER2 antibodies is administered, then treatment simplicity is maintained, but combination therapy options are needed to enhance efficacy
Solution Approach 1:
The immunoconjugates merge multiple therapeutic mechanisms (targeted binding, ADCC, and direct cytotoxicity) into a single administered agent, maintaining ease of operation through single-agent administration while achieving the enhanced efficacy of combination therapy through the integrated multi-mechanism action
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-HER2 antibodies and immunoconjugates effectively inhibit HER2-positive cancer cell proliferation and provide therapeutic benefits, including tumor reduction and improved response rates in neoadjuvant settings.
Implementation Method 1
anti-HER2 antibodies and immunoconjugates that bind specifically to HER2
Implementation Method 2
effectively inhibit HER2-positive cancer cell proliferation
Data Source
AI summary
The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.